APRILBIO CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15,530 KRW | +5.22% |
|
+0.32% | -7.83% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 3,63,525 | 3,37,337 | 3,37,337 | - |
| Enterprise Value (EV) 2 | 363.5 | 337.3 | 255.3 | 285.3 |
| P/E ratio | - | -23.5 x | -34.1 x | -37.8 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 1,818 x | - | 15 x | 25 x |
| EV / Revenue | 1,818 x | - | 11.3 x | 21.1 x |
| EV / EBITDA | - | -26.5 x | 39.3 x | -95.1 x |
| EV / FCF | - | 252 x | -42.6 x | -14.6 x |
| FCF Yield | - | 0.4% | -2.35% | -6.83% |
| Price to Book | - | 5.31 x | 4.82 x | 5.06 x |
| Nbr of stocks (in thousands) | 21,574 | 21,722 | 21,722 | - |
| Reference price 3 | 16,850 | 15,530 | 15,530 | 15,530 |
| Announcement Date | 27/04/23 | 12/03/24 | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net sales 1 | 0.2 | - | 22.5 | 13.5 |
| EBITDA 1 | - | -12.71 | 6.5 | -3 |
| EBIT 1 | - | -13.39 | 6 | -3.5 |
| Operating Margin | - | - | 26.67% | -25.93% |
| Earnings before Tax (EBT) 1 | - | -14.13 | -10 | -9 |
| Net income 1 | -8.959 | -14.13 | -10 | -9 |
| Net margin | -4,479.64% | - | -44.44% | -66.67% |
| EPS 2 | - | -662.0 | -455.0 | -411.0 |
| Free Cash Flow 3 | - | 1,000 | -6,000 | -19,500 |
| FCF margin | - | - | -26,666.67% | -1,44,444.44% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 27/04/23 | 12/03/24 | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | - | 85 | 82 | 52 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 2 | - | 1,000 | -6,000 | -19,500 |
| ROE (net income / shareholders' equity) | - | -20.7% | 9.8% | -6.15% |
| ROA (Net income/ Total Assets) | - | -17.1% | 6.75% | -4.35% |
| Assets 1 | - | 76.02 | -148.1 | 206.9 |
| Book Value Per Share 3 | - | 2,927 | 3,220 | 3,072 |
| Cash Flow per Share 3 | - | -561.0 | -442.0 | -401.0 |
| Capex 1 | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 27/04/23 | 12/03/24 | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
15,530
KRW
Average target price
27,000
KRW
Spread / Average Target
+73.86%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.83% | 25Cr | |
| +8.29% | 11TCr | |
| +10.21% | 10TCr | |
| -11.90% | 2.24TCr | |
| +0.35% | 2.23TCr | |
| -5.52% | 1.91TCr | |
| -37.36% | 1.8TCr | |
| -5.17% | 1.79TCr | |
| +7.70% | 1.43TCr | |
| +37.65% | 1.25TCr |
- Stock Market
- Equities
- A397030 Stock
- Financials AprilBio Co.,Ltd.